Showing results (41-50 of 443) with videos related to
Sort By:
Pageof 45
The Oncologist|January 7, 2015
Advances in anticancer immunotoxin therapyChristine Alewine, Raffit Hassan, Ira PastanJournal of Immunological Methods|September 16, 2003
DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteinsSatoshi Nagata, Giuliana Salvatore, Ira PastanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Mesothelin: a new target for immunotherapyRaffit Hassan, Tapan Bera, Ira PastanCellular Immunology|September 15, 2018
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1Ronit Mazor, Emily King, Ira PastanClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
New Life for Immunotoxin Cancer TherapyRaffit Hassan, Christine Alewine, Ira PastanImmunological Reviews|February 12, 2016
Immunogenicity of therapeutic recombinant immunotoxinsRonit Mazor, Masanori Onda, Ira PastanJournal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cellsSatoshi Nagata, Tomoko Ise, Ira PastanMolecular Cancer Therapeutics|March 21, 2022
GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt SignalingJiajia Pan, Nan Li, Alex Renn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2006
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing miceYuJian Zhang, Laiman Xiang, Raffit Hassan, et al.Clinical Orthopaedics and Related Research|January 22, 2005
TP-3 immunotoxins improve antitumor activity in mice with osteosarcomaMasanori Onda, Øyvind S Bruland, Ira PastanPageof 45